SOURCE: Lipid Sciences

October 04, 2007 12:23 ET

Lipid Sciences' HDL Mimetic Peptide Shown to Significantly Increase HDL

In Vivo Data Presented by Dr. H. Bryan Brewer, Jr. at DALM 2007

PLEASANTON, CA--(Marketwire - October 4, 2007) - DALM 2007 -- Lipid Sciences, Inc. (NASDAQ: LIPD) -- In a presentation made today at the XVI International Symposium on Drugs Affecting Lipid Metabolism (DALM 2007) in New York, Dr. H. Bryan Brewer, Jr., Chief Scientific Director of Lipid Sciences, Inc., announced the initial results of studies assessing the ability of Lipid Sciences' HDL mimetic peptide, LSI 518P, to mimic the principal functional characteristics of HDL. These studies showed that LSI 518P: 1)Significantly raised HDL in a mouse model following a single dose of the peptide; 2)Was highly effective in removing cholesterol from cholesterol-filled cells by the ABCA1 transporter; and 3)Decreased CD11B adhesion molecules -- thereby reducing the potential inflammation in the vessel wall associated with atherosclerosis.

Dr. Brewer noted, "The results of these studies confirm earlier in vitro analyses that LSI 518P is highly effective and specific in cholesterol efflux -- removing cholesterol from cholesterol-laden cells. The in vivo animal studies clearly demonstrated that Lipid Sciences' LSI 518P substantially increased HDL in this well-accepted animal model. Increased HDL will enhance the process of Reverse Cholesterol Transport -- removing excess lipids from the arterial wall to reduce plaque build-up. Most significantly, this initial assessment of Lipid Sciences' LSI 518P demonstrates that our lead mimetic peptide candidate possesses HDL efflux and anti-inflammatory properties similar to naturally-occurring ApoA-I, thus making it the ideal mimetic peptide."

Commenting on these study results, Dr. S. Lewis Meyer, President and Chief Executive Officer of Lipid Sciences, remarked, "We are highly confident that our LSI 518P will be a key player in the new frontier of HDL therapy. This synthetic HDL will provide a fast-acting intervention for Acute Coronary Syndrome (ACS) patients and has the potential to stop that patient's next heart attack. Statistics show that over 15 million Americans have suffered from ACS and that once every 15 seconds someone in the United States is having a heart attack. Furthermore, there is a greater than 20% chance that these patients will have another coronary event within 18 months. Clearly this patient population represents a growing unmet clinical need in the almost $400 billion cardiovascular disease marketplace. We intend to demonstrate that our LSI 518P can provide an efficacious and cost-effective solution to this daunting challenge."

About DALM 2007 -- The Drugs Affecting Lipid Metabolism (DALM) Symposium is a prestigious gathering of international researchers focusing primarily on the pharmacological control of plasma lipids -- a recognized risk factor in atherosclerosis.

Lipid Sciences, Inc. is a development-stage biotechnology company engaged in the research and development of products and processes intended to treat major medical indications, in which lipids, or fat components, play a key role. The Company's HDL Therapy platform (HDL Selective Delipidation and HDL Mimetic Peptides) aims to develop treatments to reverse atherosclerosis, a systemic disease of the blood vessels caused by the build-up of cholesterol-filled plaques in the vascular system and, most critically, in the coronary arteries. Regression of such plaques may have a major impact on reducing the risk of acute coronary events. The Company's Viral Immunotherapy platform focuses on the removal of the lipid coatings from lipid-enveloped viruses and other lipid-containing infectious agents by applying Lipid Sciences' proprietary delipidation technologies. The Company believes that removing the virus' protective lipid coating enhances the processing and presentation of viral proteins to stimulate the body's immune system to effectively fight the disease. Conditions that could potentially be impacted by these technologies include HIV, Hepatitis B and Hepatitis C, West Nile, SARS, influenza, and a broad range of animal health applications.

Forward-Looking Statements: This release contains forward-looking statements concerning plans, objectives, goals, strategies, study results, anticipations, expectations, future events or performance as well as all other statements that are not statements of historical fact. The forward-looking statements contained in this release reflect our current beliefs and expectations on the date of this release. Actual results, performance or outcomes may differ materially from what is expressed in the forward-looking statements. Readers should refer to the documents filed by us with the SEC, specifically the most recent reports on Form 10-K and Form 10-Q which identify important risk factors that could cause actual results to differ from those contained in the forward-looking statements. In addition to those risk factors, other factors that could cause actual results to differ materially include the following: Our inability to obtain adequate funds; the significant losses we have incurred to date, and our expectation that we will incur substantial losses in the future; the failure of our technologies to prove safe or effective; our inability to obtain regulatory approval for our technologies, which are only in the clinical development stage; delay or failure to complete pre-clinical animal studies or clinical trials; our inability to add additional clinical trial sites; our dependence on our license agreement with Aruba International B.V.; our reliance on collaborations with strategic partners and consultants; competition in our industry, including the development of new products by others that may provide alternative or better therapies; failure to secure and enforce our intellectual property rights; risks associated with use of biological and hazardous materials; acceptance of our potential products by healthcare providers and patients; our exposure to product liability claims; and our dependence on key personnel.

This release should be read in conjunction with the consolidated financial statements and notes thereto included in our most recent reports on Form 10-K and Form 10-Q. Copies are available through the SEC's Electronic Data Gathering Analysis and Retrieval system (EDGAR) at Lipid Sciences assumes no obligation to update the forward-looking statements included in this document.

Press releases for Lipid Sciences, Inc. are available on our website: If you would like to receive our press releases via email, please contact:

Contact Information

    Deborah S. Lorenz
    Vice President, Investor Relations and
    Corporate Communications
    Lipid Sciences, Inc.
    Email Contact